Please login to the form below
progressive supranuclear palsy
This page shows the latest progressive supranuclear palsy news and features for those working in and with pharma, biotech and healthcare.
Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug
The investigational treatment, UCB0107, is a monoclonal antibody drug being developed by UCB as a potential treatment for patients with tauopathies, such as progressive supranuclear palsy (PSP) and Alzheimer’s disease. ... Tau pathology is indicated in
Latest news
-
Biogen grows in Q2, but Spinraza performance a concern
Biogen has a number of significant clinical readouts over the next 18 months, but many of these remain high risk, such as the phase 3 trial of BIIB092 in progressive supranuclear ... palsy. One big binary decision awaiting the firm is a challenge
-
Spinraza keeps Biogen afloat as Tecfidra stalls
He adds: “By the end of 2020 we expect readouts across our clinical programmes in MS, progressive supranuclear palsy, ALS, Parkinson’s disease, pain, cognitive impairment associated with schizophrenia, epilepsy, stroke, ... Trial results of
-
Spinraza lifts Biogen ahead of Alzheimer’s data
enrolment in phase 2 studies of new MS therapy opicinumab and BIIB092 for progressive supranuclear palsy.
-
Celgene bulks up pipeline again with $2.1bn Prothena deal
The three targets at the centre of the collaboration with Ireland-based Prothena include: tau protein, already a focus in Alzheimer’s research and other conditions like progressive supranuclear palsy (PSP);
-
AbbVie takes anti-tau drug into phase II for Alzheimer's
drugs. The antibody - called ABBV-8E12 - is being tested in two phase II trials, one in patients with early Alzheimer's and a second in progressive supranuclear palsy (PSP), a rare ... We see potential in ABBV-8E12 and tau-focused approaches to
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Deal Watch - May 2017
BMS. Biogen (US). Licence. Anti-tau antibody pre phase 2 for progressive supranuclear palsy.
-
Deal Watch table for April 2014
750. iPerian/ BMS. Acquisition. CNS/ Tauopathies, mAB IPN007 to treat progressive supranuclear palsy (PSP) (preclinical).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- FDA approves Roche’s Actemra COVID-19 trial
- Roche’s Ocrevus boasts positive long-term data in MS
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Wordbird
Wordbird is a healthcare communications agency with creative, compelling copy at its heart....
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
